SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019

SMi Group15 - 16 May 2019, London, UK.
The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%. Injectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous. These are examples of conventional drug delivery. Recently, there has been a focus on novel drug delivery, including needle-free injectors, and transdermal patches. Long acting injectables (LAI) are developing fast as a push towards patient centric devices drives the industry. Habitually, injectables were used for delivery of hormones, vaccines and insulin but as technology advances the application is continuing to expand. Now there is an emphasis on finding solutions to chronic conditions and the biological drugs required involve formulation development challenges for proteins, including high viscosity and high volume. Self-administrative, connected, and ergonomic devices are the new drive. Self-injectable devices include pen injectors for diabetic patients. The wealth of expansion available in the field of connected devices is huge. The regulatory landscape is challenging as it evolves rapidly with the market demand for new devices.

The benefits of attending

Developing on last year's success, this event assembles an international audience to include regulatory, device design, packaging and formulation professionals. The devices need to be designed for the new generation of drugs and they need to provide safety with a strong patient focus. This event is will help inspire you to help drive this industry forward and learn about the predicted market trends, critical digital and chemical developments and the push for patient compliance in a changing regulatory landscape.

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:

  • Life cycle management for developing devices that are both user friendly and revenue effective
  • Device design considerations
  • Long acting injectables and bringing these therapeutics to market with case studies
  • Connected devices, GDPR and cyber security programs
  • Developments in primary packaging
  • Growth in transdermal delivery and subcutaneous infusion devices
  • Digital health partnerships
  • Large volume patch pump innovation examples

Who should attend

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

Featured Speakers

  • Bjorg K. Hunter, Device Engineering Manager, GSK
  • Miranda Newbery, Human Factors Consultant, Inspired Usability
  • Blake Green, Regulatory Affairs Senior Manager, Devices, Amgen
  • Quentin Le Masne, Head of Engineering team - Electro-Medical / Drug Delivery Devices, Merck
  • Vasco Filipe, Formulation and Drug Process Development Section Head for Biologics, Sanofi
  • Stephen Paboojian, Senior Project Leader I for Device Development, Novartis
  • Tom Lawrie-Fussey, Digital Services Specialist, Cambridge Design Partnership
  • Terry Reed, Director of Business development, AstraZeneca
  • Joel Richard, Head of Technical and Pharmaceutical Operations, MedinCell

For further information and to register, please visit:
http://www.injectable-drug-delivery.com/worldpharmwl

Early Bird Discounts

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...